Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial
Aaron I. Vinik, Vera Bril, Peter Kempler, William J. Litchy, Solomon Tesfaye, Karen L. Price, Edward J. Bastyr
Dive into the research topics of 'Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial'. Together they form a unique fingerprint.